Dr. Dreicer on Sequencing Therapies for Patients with Prostate Cancer

Robert Dreicer, MD, MS, FACP, FASCO, Division of Hematology and Oncology, Department of Medicine, University of Virginia School of Medicine, discusses sequencing therapies in prostate cancer.

If researchers can better predict which patients will respond to specific treatments and/or will not benefit from sequential use, they will have better insight on sequencing overall, Dreicer explains. Practitioners will be able to initially administer AR-targeted therapies, followed by chemotherapy or a novel agent.

Researchers are also determining how to include radium-223 into the treatment paradigm for prostate cancer. Ongoing clinical trials are anticipated to provide insight on radium-223 combinations with next-generation AR-targeted therapies, Dreicer says.

Given the rapid approval of therapies to treat prostate cancer, Dreicer says it is not surprising that researchers are unsure how to sequence them. He predicits there will be better knowledge of this within the next five years.